Robert Bettiker is an Infectious Disease physician affiliated with Temple University. OpenAlex indexes 22 publications with 461 citations (h-index 10); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3401 N Broad St
Philadelphia, PA 191405103
Telephone
215-707-3807Registry record last updated 20 Apr 2018.
Clinical trials
- Undiagnosed Hepatitis C Infection in an Urban Hospital
Sponsor: Temple University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ViiV Healthcare CompanyProgram year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
46.9%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor17.4%Dovato100%Part D<11 patientsAzole Antifungal10.1%Ketoconazole100%Part D<11 patients+ 3 more classes in this area
Cardiovascular
24.2%Statin6.8%Atorvastatin Calcium100%Part D<11 patientsBeta blocker5.8%Carvedilol100%Part D<11 patients+ 2 more classes in this area
Genitourinary & hormones
11.1%Cholinergic Muscarinic Antagonist5.8%Oxybutynin Chloride Er100%Part D<11 patientsbeta3-Adrenergic Agonist5.3%Myrbetriq100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Experiences of LGBTQIA+ medical students: gaps and challenges during preclinical education
BMC Medical Education
2026 - Perceptions of Long-Acting Injectable Antiretroviral Treatment Regimens in a United States Urban Academic Medical Center
Journal of the International Association of Providers of AIDS Care (JIAPAC)
2020 - 1040. Real-World Implementation of Dolutegravir-Lamivudine to Achieve and Maintain HIV-1 Viral Suppression at an Academic Medical Center
Open Forum Infectious Diseases
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Gerard Criner, MD
Temple University
Yoshiya Toyoda, MD, PhD
Temple University
Lyle Ostrow, MD, PhD
Temple University
Michel Pontari, MD
Temple University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”